{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:55:02Z","timestamp":1778781302216,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2009,12,19]],"date-time":"2009-12-19T00:00:00Z","timestamp":1261180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2010,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare the ocular surface tolerability of latanoprost 0.005% preserved with 0.02% benzalkonium chloride (BAK), bimatoprost 0.03% preserved with 0.005% BAK, and travoprost 0.004% preserved with the proprietary preservative system sofZia in patients previously treated with latanoprost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This randomized, multicenter, investigator-masked, parallel-group study enrolled patients with open-angle glaucoma or ocular hypertension who had been on latanoprost monotherapy for at least 4 weeks. At baseline, patients were randomized to receive once-daily bimatoprost (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200935), latanoprost (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200938), or travoprost (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200933) monotherapy for 3 months. Follow-up visits were at week 1, month 1, and month 3. The primary outcome measure was physician-graded conjunctival hyperemia at month 3. Secondary outcome measures included corneal staining with fluorescein and tear breakup time (TBUT).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      There were no significant differences among the treatment groups in conjunctival hyperemia scores, corneal staining, or TBUT at the latanoprost-treated baseline or at any follow-up visit. Baseline mean (standard error of the mean) values were as follows\u2014conjunctival hyperemia: bimatoprost 0.74 (0.10), latanoprost 0.74 (0.11), travoprost 0.86 (0.12),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.692; corneal staining: bimatoprost 0.59 (0.12), latanoprost 0.70 (0.13), travoprost 0.48 (0.11),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.423; TBUT (in seconds): bimatoprost 9.1 (1.0), latanoprost 8.6 (0.8), travoprost 7.9 (0.8),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.578. Month 3 values were as follows\u2014conjunctival hyperemia: bimatoprost 0.80 (0.12), latanoprost 0.74 (0.10), travoprost 0.98 (0.13),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.340; corneal staining: bimatoprost 0.71 (0.78), latanoprost 0.47 (0.64), travoprost 0.36 (0.62),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.110; TBUT (in seconds): bimatoprost 9.7 (5.3), latanoprost 9.2 (5.3), travoprost 9.7 (6.3),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.909.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>There were no significant differences among bimatoprost (preserved with 0.005% BAK), latanoprost (preserved with 0.02% BAK), and travoprost (preserved with sofZia) in objective clinical measures of ocular tolerability, including physician-graded hyperemia, corneal staining, and TBUT after 3 months of treatment. Longer-term studies are needed to further evaluate the ocular surface tolerability of these prostaglandin analogs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2009.0134","type":"journal-article","created":{"date-parts":[[2009,12,19]],"date-time":"2009-12-19T17:17:17Z","timestamp":1261243037000},"page":"287-292","source":"Crossref","is-referenced-by-count":31,"title":["Ocular Surface Tolerability of Prostaglandin Analogs in Patients with Glaucoma or Ocular Hypertension"],"prefix":"10.1177","volume":"26","author":[{"given":"Jess T.","family":"Whitson","sequence":"first","affiliation":[{"name":"UT Southwestern Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Trattler","sequence":"additional","affiliation":[{"name":"Center for Excellence in Eye Care"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Matossian","sequence":"additional","affiliation":[{"name":"Matossian Eye Associates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Williams","sequence":"additional","affiliation":[{"name":"Allergan, Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Hollander","sequence":"additional","affiliation":[{"name":"Allergan, Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,12,19]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2006.00001.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.03.006"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850114"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.1.45"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000183538.53017.69"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0939-6411(01)00246-6"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02853166"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-1067"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-1331"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27492007000600005"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850305"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.138768"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-008-0078-y"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31815cf651"},{"key":"e_1_3_3_16_2","first-page":"292","volume-title":"The Preocular Tear Film in Health, Disease and Contact Lens Wear","author":"Champeau E.J.","year":"1986","unstructured":"Champeau E.J., , Edelhauser H.F. Effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate. Holly F.J. The Preocular Tear Film in Health, Disease and Contact Lens Wear. Lubbock, TX: Dry Eye Institute, Inc., 292\u2013302. 1986."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0272-0590(89)90286-8"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01827-5"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01177-1"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(03)00098-9"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.158071"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(92)31847-0"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006051725115"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2000.078001037.x"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1201\/9780203912072.ch3"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30407-7"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210801800315"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850204"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200312000-00008"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31815c5f4f"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31815a3472"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ijg.0000212274.50229.c6"},{"key":"e_1_3_3_33_2","first-page":"291","article-title":"Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients","volume":"3","author":"Horsley M.B.","year":"2009","unstructured":"Horsley M.B., , Kahook M.Y. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin. Ophthalmol., 3:291\u2013295. 2009.","journal-title":"Clin. Ophthalmol."}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2009.0134","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2009.0134","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2009.0134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:35:55Z","timestamp":1777646155000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2009.0134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,19]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6,1]]}},"alternative-id":["10.1089\/jop.2009.0134"],"URL":"https:\/\/doi.org\/10.1089\/jop.2009.0134","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,19]]}}}